申请人:Pfizer Inc.
公开号:US04230714A1
公开(公告)日:1980-10-28
A series of 2-(imidazol-1-ylmethyl)pyridines and 2-(imidazol-1-ylmethyl)quinolines has been prepared, including their pharmaceutically acceptable acid addition salts. These particular compounds are useful in therapy for the treatment of ischaemic heart disease, migraine, transient ischaemic attack and stroke. Preferred member compounds include 2-(imidazol-1-ylmethyl)-3-methoxypyridine, 2-(imidazol-1-ylmethyl)-3-methoxy-6-methylpyridine and 2-(imidazol-1-ylmethyl)-3-benzyloxypyridine, respectively. Alternate methods of preparation are provided and the principal synthetic routes leading to the preferred compounds are described in some detail.
一系列2-(咪唑-1-基甲基)吡啶和2-(咪唑-1-基甲基)喹啉已经制备出来,包括它们的药学上可接受的酸盐。这些特定的化合物在治疗缺血性心脏病、偏头痛、短暂性脑缺血发作和中风方面非常有用。首选的成员化合物分别包括2-(咪唑-1-基甲基)-3-甲氧基吡啶、2-(咪唑-1-基甲基)-3-甲氧基-6-甲基吡啶和2-(咪唑-1-基甲基)-3-苄氧基吡啶。提供了备用制备方法,并详细描述了导致首选化合物的主要合成路线。